NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,192.460954259421,7.162826736902205,55.57264190552241,1.74486104349614,8.95647120560566,158.168860358016,percent_activity,2,26.869413616817,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.44098205419182,1.44098205419182,1.37770276559329,20,cell cycle
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,2.86006091441973,7.813345190365382,30.147766312072307,1.47925514021489,0.122016065451132,2.85986524216955,log2_fold_induction,2,0.366048196353396,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.37508226179244,1.37508226179244,1.35997158677004,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,146.47930997742,5.059597449143402,26.926571660800676,1.43018106178219,9.65026114229828,146.475078726871,percent_activity,2,28.9507834268948,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.35411686440871,1.35411686440871,1.31089474803814,20,cell cycle
ACEA_ER_AUC_viability,"Data from the assay component ACEA_ER_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,94.53332154530953,4.7266660772654765,56.48453011845137,1.7519295203126868,5.860768439731081,75.07191202280579,percent_activity,2,20,"[""Only highest conc above baseline, active""]",1.5082170130098715,1.478434193124727,1.344871060773667,20,cell cycle
ATG_Ahr_CIS_dn,ATG_Ahr_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001612.1,AHR,aryl hydrocarbon receptor,https://www.ncbi.nlm.nih.gov/gene/196,,,Active,2.6730167634893514,2.698172526708425,29.95838126194739,1.4765183434734783,0.19813534805724511,2.227513969592222,log2_fold_induction,1.30102999566398,0.9906767402862255,,0.9506161448288621,0.23325594287384988,-0.7055595896454891,20,dna binding
ATG_CAR_TRANS_dn,ATG_CAR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001070948.1,NR1I3,"nuclear receptor subfamily 1, group I, member 3",https://www.ncbi.nlm.nih.gov/gene/9970,,,Active,1.0239281104734237,1.0153139721178077,7.331053166430152,0.8651663691178051,0.20169684227582294,1.0235877690218735,log2_fold_induction,1.30102999566398,1.0084842113791146,"[""Only one conc above baseline, active"",""Borderline active""]",1.0920316878069518,0.8851383221248624,0.7458853718234113,20,nuclear receptor
ATG_C_EBP_CIS_up,"Data from the assay component ATG_C_EBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_C_EBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CEBPB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005185.2,CEBPB,"CCAAT/enhancer binding protein (C/EBP), beta",https://www.ncbi.nlm.nih.gov/gene/1051,,,Active,0.7012753377955712,1.4033262623003728,9.543819166193591,0.9797222018412155,0.09994473226005482,0.6993925086431141,log2_fold_induction,1.30102999566398,0.4997236613002741,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.0290251669418378,0.963876389591628,0.8604176226013188,20,dna binding
ATG_CRE_CIS_up,"Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006359.3,CREB3,cAMP responsive element binding protein 3,https://www.ncbi.nlm.nih.gov/gene/10488,,,Active,1.6105271721714782,2.20456652915081,10.5693878680235,1.0240498356293053,0.14610828486013952,1.3421059768249906,log2_fold_induction,1.30102999566398,0.7305414243006976,"[""Only one conc above baseline, active""]",0.9910727953093952,0.8497597536886927,0.6347415886634229,20,dna binding
ATG_DR4_LXR_CIS_dn,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_009052.3|NP_005684.2","NR1H2 | NR1H3","nuclear receptor subfamily 1, group H, member 2 , nuclear receptor subfamily 1, group H, member 3","https://www.ncbi.nlm.nih.gov/gene/7376 , https://www.ncbi.nlm.nih.gov/gene/10062",,,Active,1.63065476506935,2.7568094625654904,5.931783720763844,0.7731853077995059,0.11830014277097414,1.6076444988301883,log2_fold_induction,1.30102999566398,0.5915007138548707,,0.7031930301592204,0.6142640705026056,0.500267956047045,20,nuclear receptor
ATG_DR5_CIS_up,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_000955.1|NP_001277145.1|NP_000957.1","RARA | RARB | RARG","retinoic acid receptor, alpha , retinoic acid receptor, beta , retinoic acid receptor, gamma","https://www.ncbi.nlm.nih.gov/gene/5914 , https://www.ncbi.nlm.nih.gov/gene/5915 , https://www.ncbi.nlm.nih.gov/gene/5916",,,Active,0.7479513774965446,1.260127210587189,7.640986397821462,0.8831494265702898,0.11871045577184501,0.7476128383657127,log2_fold_induction,1.30102999566398,0.593552278859225,"[""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",0.9562512300322827,0.8779648766380721,0.7638690697299234,20,nuclear receptor
ATG_E_Box_CIS_dn,ATG_E_Box_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_009053.1,USF1,upstream transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/7391,,,Active,1.2105369950015206,2.562590947143049,5.631458962942521,0.7506209237094397,0.09447758303767596,1.1941912566536943,log2_fold_induction,1.30102999566398,0.4723879151883798,,0.6934502298484444,0.5988270514608237,0.4691866806360704,20,dna binding
ATG_EGR_CIS_up,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_001955.1,EGR1,early growth response 1,https://www.ncbi.nlm.nih.gov/gene/1958,,,Active,1.2768656856700016,1.8301874962841422,5.75792300575167,0.7602658532477331,0.13953386614895374,1.276688068122151,log2_fold_induction,1.30102999566398,0.6976693307447688,,0.7703688297731939,0.7212883458618556,0.6409855392000386,20,dna binding
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,1.8781955416300886,1.6994889797108783,8.646985401956313,0.9368647257901048,0.22103062321117403,1.8759042618394504,log2_fold_induction,1.30102999566398,1.10515311605587,"[""Only one conc above baseline, active""]",0.9562708624276616,0.9039784235204879,0.8175613814184335,20,nuclear receptor
ATG_Ets_CIS_dn,ATG_Ets_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_005229.1,ETS1,v-ets avian erythroblastosis virus E26 oncogene homolog 1,https://www.ncbi.nlm.nih.gov/gene/2113,,,Active,0.5995173975937845,1.654683810684021,8.716889452887653,0.940361538321869,0.07246307647694375,0.5987372842180458,log2_fold_induction,1.30102999566398,0.3623153823847187,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",0.963359019030034,0.9097382542690146,0.8210738025171116,20,dna binding
ATG_FoxO_CIS_dn,ATG_FoxO_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_002006.2|NP_001446.1","FOXO1 | FOXO3","forkhead box O1 , forkhead box O3","https://www.ncbi.nlm.nih.gov/gene/2308 , https://www.ncbi.nlm.nih.gov/gene/2309",,,Active,0.8296835124211454,1.7615975925201666,9.213940510012783,0.9644454038948915,0.09419671279570589,0.8280098068234808,log2_fold_induction,1.30102999566398,0.4709835639785295,"[""Only one conc above baseline, active""]",0.9792341476949399,0.92857157908945,0.8451292752575559,20,dna binding
ATG_GATA_CIS_dn,ATG_GATA_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_002040.1,GATA1,GATA binding protein 1 (globin transcription factor 1),https://www.ncbi.nlm.nih.gov/gene/2623,,,Active,0.3638672060537369,1.1095778179577571,8.240020592123717,0.9159282970168399,0.06558660423177091,0.36356474584160137,log2_fold_induction,1.30102999566398,0.3279330211588546,"[""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.0359894507962344,0.9247978455349614,0.7966216650002058,20,dna binding
ATG_GLI_CIS_up,"Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GLI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005260.1,GLI1,GLI family zinc finger 1,https://www.ncbi.nlm.nih.gov/gene/2735,,,Active,0.7929234299240304,2.0626035707823513,5.902622852929076,0.7710450349365232,0.07688568381788191,0.7577329431886033,log2_fold_induction,1.30102999566398,0.38442841908940956,,0.7605463278837434,0.616985674535609,0.39115008901932163,20,dna binding
ATG_HIF1a_CIS_up,"Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HIF1a_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001521.1,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",https://www.ncbi.nlm.nih.gov/gene/3091,"[122,123,220,150,122,123,220,150]",[801],Active,0.9535986437748727,1.2457427140257027,6.047763790891411,0.7815948204700448,0.15309720587379613,0.9534816213710097,log2_fold_induction,1.30102999566398,0.7654860293689807,"[""Hit-call potentially confounded by overfitting""]",0.8577847394602759,0.7776062874168161,0.6623145063379351,20,dna binding
ATG_HNF6_CIS_dn,ATG_HNF6_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_004489.1,ONECUT1,one cut homeobox 1,https://www.ncbi.nlm.nih.gov/gene/3175,,,Active,0.8016607016216688,2.231935170276144,7.789315484856472,0.8914992941024007,0.07183548270557376,0.8012371322061206,log2_fold_induction,1.30102999566398,0.3591774135278688,,0.8801756949989866,0.8371797746812759,0.772217744217887,20,dna binding
ATG_HSE_CIS_up,"Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HSE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.",NP_005517.1,HSF1,heat shock transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/3297,,,Active,3.3894523393366285,7.136358874304133,4.1577604598110955,0.6188594647984962,0.09499108436211133,3.3879801347800873,log2_fold_induction,1.30102999566398,0.47495542181055667,,0.4613281421277501,0.41148944501734663,0.42807252028994736,20,dna binding
ATG_IR1_CIS_dn,ATG_IR1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001193922.1,NR1H4,"nuclear receptor subfamily 1, group H, member 4",https://www.ncbi.nlm.nih.gov/gene/9971,,,Active,1.6855620774703381,3.4408146013069754,7.903585120276302,0.8978241349318452,0.09797459455270192,1.4046350646555381,log2_fold_induction,1.30102999566398,0.4898729727635096,,0.6727336465104088,0.5055968350694438,0.3435747705049089,20,nuclear receptor
ATG_ISRE_CIS_dn,ATG_ISRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_002189.1,IRF1,interferon regulatory factor 1,https://www.ncbi.nlm.nih.gov/gene/3659,,,Active,0.9788742292651396,1.3844997981015499,8.37095865196425,0.9227751967528197,0.14140474857524557,0.9779532934262068,log2_fold_induction,1.30102999566398,0.7070237428762278,"[""Only one conc above baseline, active""]",0.9746642809493171,0.9082196903309369,0.8034923573584052,20,dna binding
ATG_MRE_CIS_up,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005946.2,MTF1,metal-regulatory transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/4520,,,Active,1.2777216121351316,2.1244655043058405,6.27204170252585,0.7974089372906434,0.12028640705584168,1.2775714379103604,log2_fold_induction,1.30102999566398,0.6014320352792084,,0.791040670087019,0.7467881427117526,0.678128622007526,20,dna binding
ATG_Myb_CIS_dn,ATG_Myb_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,CAE82649.1,MYB,v-myb avian myeloblastosis viral oncogene homolog,https://www.ncbi.nlm.nih.gov/gene/4602,,,Active,0.5433425101327403,1.843379408875513,8.059616493483002,0.9063143769506625,0.05895069756303578,0.5429788355134766,log2_fold_induction,1.30102999566398,0.2947534878151789,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",0.915561856553609,0.8667563109708194,0.7870294996648662,20,dna binding
ATG_NFI_CIS_up,"Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NFI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.",NP_001128145.1,NFIA,nuclear factor I/A,https://www.ncbi.nlm.nih.gov/gene/4774,,,Active,0.9172504399898591,2.1772960555651784,7.008125723827038,0.8456018843521702,0.08425592262892893,0.917037905333391,log2_fold_induction,1.30102999566398,0.4212796131446447,,0.8367411645461712,0.793131587052153,0.7263214537313915,20,dna binding
ATG_NF_kB_CIS_dn,ATG_NF_kB_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_068810.3,NFKB1,nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,https://www.ncbi.nlm.nih.gov/gene/4790,,,Active,1.094412726960876,1.709770313191521,8.388027963972808,0.9236598696448607,0.12801868397375604,1.093364649607162,log2_fold_induction,1.30102999566398,0.6400934198687802,"[""Only one conc above baseline, active""]",0.9422702433763358,0.8902744540764294,0.8043788986272218,20,dna binding
ATG_NRF1_CIS_up,"Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear respiratory factors.",NP_005002.3,NRF1,nuclear respiratory factor 1,https://www.ncbi.nlm.nih.gov/gene/4899,,,Active,1.125842004550731,2.800149369788674,7.807911682143588,0.8925348922387301,0.08041299629924369,0.9382016704930761,log2_fold_induction,1.30102999566398,0.40206498149621844,,0.7225199196620721,0.516755830072718,0.2570860650297442,20,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,1.4569479105321945,1.8760874848506093,2.0884589573690366,0.3198259448808649,0.15531769411576343,1.4885216335931064,log2_fold_induction,0.845098040014257,0.7765884705788172,,0.35033255907434796,0.14580559554501193,-0.18686560215083015,20,dna binding
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3,POU2F1,POU class 2 homeobox 1,https://www.ncbi.nlm.nih.gov/gene/5451,,,Active,1.0041849114102466,1.4817759412770428,5.079870075665485,0.7058526047754319,0.13553802345377633,1.0033026226728392,log2_fold_induction,1.30102999566398,0.6776901172688816,,0.7454969662285544,0.6849517304105,0.5865722910147101,20,dna binding
ATG_p53_CIS_dn,ATG_p53_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,,,Active,1.308965987657176,2.047782328149347,6.937684124095442,0.8412145223314555,0.12784229746138445,1.308681544522681,log2_fold_induction,1.30102999566398,0.6392114873069222,"[""Hit-call potentially confounded by overfitting""]",0.8386806385999854,0.7933955186138602,0.7219342058877523,20,dna binding
ATG_Pax6_CIS_up,"Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Pax6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is paired box protein.",NP_000271.1,PAX6,paired box 6,https://www.ncbi.nlm.nih.gov/gene/5080,,,Active,1.5379167206176234,2.422977164872277,5.992607149171933,0.7776158080587305,0.12694438419923712,1.53271604467253,log2_fold_induction,1.30102999566398,0.6347219209961856,,0.7451456029997078,0.6753226878106183,0.5753647085186726,20,dna binding
ATG_PBREM_CIS_up,"Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PBREM_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001070948.1,NR1I3,"nuclear receptor subfamily 1, group I, member 3",https://www.ncbi.nlm.nih.gov/gene/9970,"[8,107,58,8,107,58]","[456,715]",Active,0.814299422494356,1.69851289300318,8.050376940635957,0.9058162156977598,0.09588380822409588,0.8137362617429418,log2_fold_induction,1.30102999566398,0.4794190411204794,"[""Only one conc above baseline, active""]",0.9252949558897222,0.8729835610418304,0.7865325736056296,20,nuclear receptor
ATG_PPARa_TRANS_up,"Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_005027.2,PPARA,peroxisome proliferator-activated receptor alpha,https://www.ncbi.nlm.nih.gov/gene/5465,"[51,18,318,6,36,61,58,37,166,37,6,318,51,18,166,36,61,58]",,Active,1.521711617827453,1.3150997298420686,16.358364300355813,1.2137398756895748,0.23142147827985585,1.2680930163839763,log2_fold_induction,1.30102999566398,1.1571073913992793,"[""Only one conc above baseline, active"",""Borderline active""]",1.276433872028319,1.204212955212365,1.0944595616453516,20,nuclear receptor
ATG_PXRE_CIS_dn,ATG_PXRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,,,Active,2.9201438872046674,4.381935444097707,6.583860240386712,0.8184806032684504,0.13328100901796647,2.7334689205475144,log2_fold_induction,1.30102999566398,0.6664050450898323,,0.5997262607349131,0.48794524208506085,0.42400143483005737,20,nuclear receptor
ATG_RARa_TRANS_dn,ATG_RARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_000955.1,RARA,"retinoic acid receptor, alpha",https://www.ncbi.nlm.nih.gov/gene/5914,,,Active,1.9620564259388957,1.7120870100009904,7.312289672842642,0.8640533874338254,0.22920055049512475,1.961430901598532,log2_fold_induction,1.30102999566398,1.1460027524756238,,0.8824867554929011,0.8305549459615598,0.7447730674051598,20,nuclear receptor
ATG_RXRb_TRANS_up,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_068811.1,RXRB,"retinoid X receptor, beta",https://www.ncbi.nlm.nih.gov/gene/6257,,,Active,1.4655087644983325,1.4752514777835064,13.548595638322022,1.1318942813258654,0.19867917932204862,1.2212573061968766,log2_fold_induction,1.30102999566398,0.9933958966102431,"[""Only one conc above baseline, active""]",1.2101283282306208,1.0921855949520496,0.9008213073122795,20,nuclear receptor
ATG_Sox_CIS_up,"Data from the assay component ATG_Sox_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sox_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SOX1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.",NP_005977.2,SOX1,SRY (sex determining region Y)-box 1,https://www.ncbi.nlm.nih.gov/gene/6656,,,Active,0.5760686861867208,1.3132924867451652,16.34449362068853,1.2133714699670215,0.08772892436389956,0.4800572911292514,log2_fold_induction,1.30102999566398,0.4386446218194978,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.2765884771252813,1.2039505122175287,1.0936921660328345,20,dna binding
ATG_Sp1_CIS_up,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_612482.2,SP1,Sp1 transcription factor,https://www.ncbi.nlm.nih.gov/gene/6667,"[148,148]",,Active,1.2640133587035847,2.4058270763965033,6.844159587084933,0.8353201275467846,0.10507931938290839,1.2637722764001447,log2_fold_induction,1.30102999566398,0.525396596914542,,0.8168286335733053,0.7755044943069094,0.7160397750318332,20,dna binding
ATG_SREBP_CIS_up,"Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",NP_004167.3,SREBF1,sterol regulatory element binding transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/6720,"[62,61,58,34,34,62,61,58]",,Active,0.6061594296287971,1.668288267236948,5.7647654346521575,0.7607816407705768,0.07266842805682862,0.5784270646712093,log2_fold_induction,1.30102999566398,0.3633421402841431,"[""Less than 50% efficacy""]",0.8321674067032928,0.6586039527275119,0.3716087346139423,20,dna binding
ATG_STAT3_CIS_dn,ATG_STAT3_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_644805.1,STAT3,signal transducer and activator of transcription 3 (acute-phase response factor),https://www.ncbi.nlm.nih.gov/gene/6774,,,Active,0.7005469207790216,1.5973136642486034,16.35942705088083,1.213768089494343,0.08771563612818246,0.5837891008672162,log2_fold_induction,1.30102999566398,0.4385781806409123,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.241742785226656,1.1861830226838206,1.0944877674394622,20,dna binding
ATG_TCF_b_cat_CIS_dn,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_003193.2|NP_001139746.1|NP_057353.1|NP_112573.1","TCF7 | TCF7L2 | LEF1 | TCF7L1","transcription factor 7 (T-cell specific, HMG-box) , transcription factor 7-like 2 (T-cell specific, HMG-box) , lymphoid enhancer-binding factor 1 , transcription factor 7-like 1 (T-cell specific, HMG-box)","https://www.ncbi.nlm.nih.gov/gene/6932 , https://www.ncbi.nlm.nih.gov/gene/6934 , https://www.ncbi.nlm.nih.gov/gene/51176 , https://www.ncbi.nlm.nih.gov/gene/83439",,,Active,1.0031960509437436,1.452232255093752,2.724386898064426,0.43526878303620453,0.13815917494257557,0.8541835452776726,log2_fold_induction,0.845098040014257,0.6907958747128778,"[""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",0.47834859129693996,0.41621794337772905,0.3159884690459166,20,dna binding
ATG_VDRE_CIS_up,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",https://www.ncbi.nlm.nih.gov/gene/7421,,,Active,1.59743247167668,2.1997887049462186,6.835056219751689,0.8347420910805081,0.1452350826317871,1.5971311740528487,log2_fold_induction,1.30102999566398,0.7261754131589355,,0.8248539932981037,0.7815031602371106,0.7154617575347035,20,nuclear receptor
ATG_Xbp1_CIS_up,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005071.2,XBP1,X-box binding protein 1,https://www.ncbi.nlm.nih.gov/gene/7494,,,Active,1.7651870650228438,2.9968503556377573,6.506005275338322,0.8133144110899163,0.11780281666064009,1.7649672509053382,log2_fold_induction,1.30102999566398,0.5890140833032005,,0.7757712163414963,0.7381281928415282,0.6940340823138001,20,dna binding
ATG_XTT_Cytotoxicity_up,"Data from the assay component ATG_XTT_Cytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, ATG_XTT_Cytotoxicity_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,89.48609183091862,1.1817195651193355,26.160517590386977,1.4176463323290345,15.145063934332322,88.55263895899941,percent_activity,2.30102999566398,75.72531967166161,"[""Borderline active"",""Borderline active""]",1.655225610323773,1.4219570233099907,1.111531339895522,20,cell cycle
BSK_3C_Eselectin_down,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2,SELE,selectin E,https://www.ncbi.nlm.nih.gov/gene/6401,,,Active,1.0229219247696468,12.918739926805323,5.000000000000001,0.6989700043360189,0.022749058062569997,1.0435002,log10_fold_induction,1.30102999566398,0.07918124604762482,,0.6989700043360189,0.6989700043360189,0.6734398077388264,20,cell adhesion molecules
BSK_3C_HLADR_down,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2,HLA-DRA,"major histocompatibility complex, class II, DR alpha",https://www.ncbi.nlm.nih.gov/gene/3122,,,Active,0.7732414841409181,9.765462438868918,5.000000000000001,0.6989700043360189,0.025758990402599997,0.77758,log10_fold_induction,1,0.07918124604762482,,0.6989700043360189,0.6989700043360189,0.43795237742169046,20,cell adhesion molecules
BSK_3C_ICAM1_down,"Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_000192.2,ICAM1,intercellular adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/3383,,,Active,1.1233066798055988,14.186524409201242,10,1,0.016926969131288997,0.9360889,log10_fold_induction,1,0.07918124604762482,,1,1,0.7176739406309096,20,cell adhesion molecules
BSK_3C_IL8_down,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.6654746043056239,6.736823950972041,10,1,0.0329272175904,0.66391397,log10_fold_induction,1.30102999566398,0.0987816527712,,1,1,0.849004439212431,20,cytokine
BSK_3C_MCP1_down,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.8862746396344645,10.455874373636902,10,1,0.028254440453399997,0.80111986,log10_fold_induction,1.30102999566398,0.08476332136019998,,1,1,0.7513501584013421,20,cytokine
BSK_3C_MIG_down,"Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,1.1693557114614805,14.768089286674687,10,1,0.00716423639925,1.0887811,log10_fold_induction,1.30102999566398,0.07918124604762482,,1,1,0.8788627509700271,20,cytokine
BSK_3C_Proliferation_down,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.3025974798208273,11.090345782927033,2,0.3010299956639812,0.0391510930713,1.0854979,log10_fold_induction,0.698970004336019,0.1174532792139,"[""Cell viability assay fit with gnls winning model""]",0.3010299956639812,0.3010299956639812,0.29527019445127334,20,cell cycle
BSK_3C_SRB_down,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.1821194599991403,14.929285897927594,5.000000000000001,0.6989700043360189,0.02172150128694,0.98509955,log10_fold_induction,1,0.07918124604762482,"[""Cell viability assay fit with gnls winning model""]",0.6989700043360189,0.6989700043360189,0.6676199453900724,20,cell cycle
BSK_3C_Thrombomodulin_up,"Data from the assay component BSK_3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000352.1,THBD,thrombomodulin,https://www.ncbi.nlm.nih.gov/gene/7056,,,Active,0.19462692556059202,2.160371327422069,10,1,0.030029856918599995,0.19988525,log10_fold_induction,1.60205999132796,0.09008957075579999,"[""Less than 50% efficacy""]",1,1,0.8217829671295347,20,gpcr
BSK_3C_TissueFactor_down,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1,F3,"coagulation factor III (thromboplastin, tissue factor)",https://www.ncbi.nlm.nih.gov/gene/2152,,,Active,0.3904746616162823,2.9992528362770448,5.000000000000001,0.6989700043360189,0.04339688170481999,0.5542958,log10_fold_induction,1,0.13019064511446,"[""Less than 50% efficacy""]",0.6989700043360189,0.6989700043360189,0.5877148046439333,20,cytokine
BSK_3C_uPAR_down,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1,PLAUR,"plasminogen activator, urokinase receptor",https://www.ncbi.nlm.nih.gov/gene/5329,,,Active,0.7124007599971742,6.076295683449355,5.000000000000001,0.6989700043360189,0.0390808697223,0.5936673,log10_fold_induction,1,0.1172426091669,,0.6989700043360189,0.6989700043360189,0.6417102351032153,20,cytokine
BSK_3C_VCAM1_down,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.8847741005842058,11.174036084908847,5.000000000000001,0.6989700043360189,0.0189344513925,0.9163913,log10_fold_induction,1,0.07918124604762482,,0.6989700043360189,0.6989700043360189,0.6226739148357079,20,cell adhesion molecules
BSK_3C_Vis_down,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",, , , ,,,Active,0.6427371510108251,8.11729018035711,5.000000000000001,0.6989700043360189,0,0.60206,log10_fold_induction,1.30102999566398,0.07918124604762482,,0.6989700043360189,0.6989700043360189,0.585654251629707,20,cell morphology
BSK_4H_Eotaxin3_down,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_006063.1,CCL26,chemokine (C-C motif) ligand 26,https://www.ncbi.nlm.nih.gov/gene/10344,,,Active,0.779109882226437,9.579549860181691,10,1,0.027110177186399995,0.8723764,log10_fold_induction,1,0.08133053155919999,,1,1,0.7747012981467885,20,cytokine
BSK_4H_MCP1_down,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.44930613595307445,2.783517623129511,10,1,0.05380555551,0.37442178,log10_fold_induction,1,0.16141666653,"[""Less than 50% efficacy""]",1,1,0.7331860695973986,20,cytokine
BSK_4H_Pselectin_down,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_002996.2,SELP,"selectin P (granule membrane protein 140kDa, antigen CD62)",https://www.ncbi.nlm.nih.gov/gene/6403,,,Active,0.27052894794831417,2.2067752569009946,10,1,0.04086338910171,0.22544079,log10_fold_induction,1,0.12259016730513,"[""Less than 50% efficacy""]",1,1,0.6532700633444092,20,cell adhesion molecules
BSK_4H_SRB_down,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_4H_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.7580946005415643,9.574168611663376,10,1,0.02048812375239,1.0954207,log10_fold_induction,1,0.07918124604762482,"[""Noisy data""]",1,1,0.700096282196742,20,cell cycle
BSK_4H_uPAR_down,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1,PLAUR,"plasminogen activator, urokinase receptor",https://www.ncbi.nlm.nih.gov/gene/5329,,,Active,0.7775149559951633,7.033519102463175,10,1,0.03684807679098,0.64792913,log10_fold_induction,1,0.11054423037293999,,1,1,0.6773546841992517,20,cytokine
BSK_4H_VCAM1_down,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.7482237085471772,9.44950661798308,5.000000000000001,0.6989700043360189,0.0228833401839,0.82212824,log10_fold_induction,1,0.07918124604762482,,0.6989700043360189,0.6989700043360189,0.6735394672107999,20,cell adhesion molecules
BSK_4H_VEGFRII_up,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",NP_002244.1,KDR,kinase insert domain receptor (a type III receptor tyrosine kinase),https://www.ncbi.nlm.nih.gov/gene/3791,"[43,43]",,Active,0.12143408115008122,1.160456727126541,39.99999999999999,1.6020599913279623,0.03488111715312,0.121004514,log10_fold_induction,1,0.10464335145935999,"[""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.1598152763350904,20,kinase
BSK_BE3C_HLADR_down,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2,HLA-DRA,"major histocompatibility complex, class II, DR alpha",https://www.ncbi.nlm.nih.gov/gene/3122,,,Active,0.7747042197791616,9.783935697516094,5.000000000000001,0.6989700043360189,0.025097172292079997,0.64558685,log10_fold_induction,1,0.07918124604762482,,0.6989700043360189,0.6989700043360189,0.6736885187937531,20,cell adhesion molecules
BSK_BE3C_IL1a_down,"Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3,IL1A,"interleukin 1, alpha",https://www.ncbi.nlm.nih.gov/gene/3552,,,Active,0.6422252787019782,8.046057979904951,10,1,0.026606208087899996,0.6111511,log10_fold_induction,1.30102999566398,0.07981862426369998,,1,1,0.7470678848812897,20,cytokine
BSK_BE3C_IP10_down,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2,CXCL10,chemokine (C-X-C motif) ligand 10,https://www.ncbi.nlm.nih.gov/gene/3627,,,Active,0.781260357730313,9.334090011937727,5.000000000000001,0.6989700043360189,0.027899893713299997,0.79188895,log10_fold_induction,1,0.08369968113989999,,0.6989700043360189,0.6989700043360189,0.6809165704067762,20,cytokine
BSK_BE3C_MIG_down,"Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,0.9687735892386683,12.234886890463734,10,1,0.0077791965661199985,0.97281307,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.8379336128421002,20,cytokine
BSK_BE3C_MMP1_down,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),https://www.ncbi.nlm.nih.gov/gene/4312,,,Active,0.32817564338224425,3.5664734632756656,10,1,0.030672282369078,0.2734986,log10_fold_induction,1.30102999566398,0.092016847107234,"[""Less than 50% efficacy""]",1,1,0.8192547638270353,20,protease
BSK_BE3C_PAI1_down,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",https://www.ncbi.nlm.nih.gov/gene/5054,,,Active,0.524955721326814,4.692585400530424,5.000000000000001,0.6989700043360189,0.0372897295428,0.52789956,log10_fold_induction,1.60205999132796,0.11186918862840001,"[""Less than 50% efficacy""]",0.6989700043360189,0.6989700043360189,0.3773281982075875,20,cytokine
BSK_BE3C_SRB_down,"Data from the assay component BSK_BE3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_BE3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.24949132694395124,3.1508891233397707,10,1,0.005817857605706999,0.37311763,log10_fold_induction,1,0.07918124604762482,"[""Less than 50% efficacy""]",1,1,0.722514847331999,20,cell cycle
BSK_BE3C_TGFb1_down,"Data from the assay component BSK_BE3C_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",P01137.2,TGFB1,"transforming growth factor, beta 1",https://www.ncbi.nlm.nih.gov/gene/7040,,,Active,0.33420672816377717,3.152293789109931,10,1,0.0353400571692,0.36240005,log10_fold_induction,1,0.10602017150760001,"[""Less than 50% efficacy""]",1,1,0.6336043630819359,20,growth factor
BSK_BE3C_tPA_down,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_000921.1,PLAT,"plasminogen activator, tissue",https://www.ncbi.nlm.nih.gov/gene/5327,,,Active,0.5053381879619478,3.781936115458228,10,1,0.04453963724175,0.5387724,log10_fold_induction,1,0.13361891172525,"[""Less than 50% efficacy""]",1,1,0.6922472255292157,20,protease
BSK_BE3C_uPA_down,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_002649.1,PLAU,"plasminogen activator, urokinase",https://www.ncbi.nlm.nih.gov/gene/5328,,,Active,0.32721860660737556,3.9854526053237356,10,1,0.02736774958092,0.33758706,log10_fold_induction,1.60205999132796,0.08210324874276,"[""Less than 50% efficacy""]",1,1,0.7428091403770579,20,protease
BSK_BE3C_uPAR_down,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1,PLAUR,"plasminogen activator, urokinase receptor",https://www.ncbi.nlm.nih.gov/gene/5329,,,Active,0.4741690995866352,4.169300255456124,10,1,0.0379095667965,0.4825272,log10_fold_induction,1.60205999132796,0.11372870038949999,"[""Less than 50% efficacy""]",1,1,0.8032405861503998,20,cytokine
BSK_CASM3C_HLADR_down,"Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2,HLA-DRA,"major histocompatibility complex, class II, DR alpha",https://www.ncbi.nlm.nih.gov/gene/3122,,,Active,1.3053454798203306,12.405495977793722,2,0.3010299956639812,0.03507438644283,1.0877879,log10_fold_induction,1.30102999566398,0.10522315932849,,0.3010299956639812,0.3010299956639812,0.2915163362864507,20,cell adhesion molecules
BSK_CASM3C_IL6_down,"Data from the assay component BSK_CASM3C_IL6 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL6_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000591.1,IL6,interleukin 6,https://www.ncbi.nlm.nih.gov/gene/3569,,,Active,0.48081160106502374,3.964778129486172,5.000000000000001,0.6989700043360189,0.040423581964499994,0.4935818,log10_fold_induction,1.60205999132796,0.12127074589349998,"[""Less than 50% efficacy""]",0.6989700043360189,0.6989700043360189,0.543707332864793,20,cytokine
BSK_CASM3C_IL8_down,"Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.7588081476052866,9.58318017815594,10,1,0.016910900838509997,0.7558391,log10_fold_induction,1.30102999566398,0.07918124604762482,,1,1,0.8246729282804995,20,cytokine
BSK_CASM3C_LDLR_down,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""LDL receptor"".",NP_000518.1,LDLR,low density lipoprotein receptor,https://www.ncbi.nlm.nih.gov/gene/3949,"[57,57]",,Active,0.5355135835918274,6.763136605222583,5.000000000000001,0.6989700043360189,0.024506084431499996,0.44626132,log10_fold_induction,1,0.07918124604762482,"[""Less than 50% efficacy""]",0.6989700043360189,0.6989700043360189,0.6582450450847596,20,misc protein
BSK_CASM3C_MCP1_down,"Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.808745764650906,9.275446255316258,10,1,0.029064037905,0.81908226,log10_fold_induction,1,0.08719211371499999,,1,1,0.7300792545440068,20,cytokine
BSK_CASM3C_MCSF_down,"Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3,CSF1,colony stimulating factor 1 (macrophage),https://www.ncbi.nlm.nih.gov/gene/1435,,,Active,0.711795366922237,7.3637462436102705,5.000000000000001,0.6989700043360189,0.03222070865265,0.74570733,log10_fold_induction,1.60205999132796,0.09666212595794998,,0.6989700043360189,0.6989700043360189,0.6355723231405702,20,cytokine
BSK_CASM3C_MIG_down,"Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,1.258224812260377,15.89043965667827,10,1,0.015950413476900002,1.2561982,log10_fold_induction,1.30102999566398,0.07918124604762482,,1,1,0.7491435613692221,20,cytokine
BSK_CASM3C_Proliferation_down,"Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.9542624881885481,9.812849949986704,2,0.3010299956639812,0.032415404055299996,0.94634646,log10_fold_induction,1,0.09724621216589999,"[""Cell viability assay fit with gnls winning model""]",0.3010299956639812,0.3010299956639812,0.09991905912422872,20,cell cycle
BSK_CASM3C_SAA_down,"Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""apolipoproteins"".",NP_954630.1,SAA1,serum amyloid A1,https://www.ncbi.nlm.nih.gov/gene/6288,,,Active,0.46401194734741824,4.572935747049999,10,1,0.033823053213809996,0.49718493,log10_fold_induction,1.60205999132796,0.10146915964143,"[""Less than 50% efficacy""]",1,1,0.6731180960092672,20,cell adhesion molecules
BSK_CASM3C_SRB_down,"Data from the assay component BSK_CASM3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.0122003634330747,12.7833346146671,10,1,0.015242156257229997,0.9453924,log10_fold_induction,1,0.07918124604762482,"[""Noisy data""]",1,1,0.9568120898448926,20,cell cycle
BSK_CASM3C_Thrombomodulin_up,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000352.1,THBD,thrombomodulin,https://www.ncbi.nlm.nih.gov/gene/7056,,,Active,0.1077712269332451,1.074654186190014,10,1,0.0334281881304,0.1296989,log10_fold_induction,1.30102999566398,0.10028456439120001,"[""Less than 50% efficacy"",""Borderline active""]",1,1,0.5813913988617614,20,gpcr
BSK_CASM3C_TissueFactor_down,"Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1,F3,"coagulation factor III (thromboplastin, tissue factor)",https://www.ncbi.nlm.nih.gov/gene/2152,,,Active,0.34821930154026803,3.045582367375637,0.6,-0.2218487496163564,0.038111955781199996,0.2911149,log10_fold_induction,1,0.11433586734359999,"[""Less than 50% efficacy""]",-0.2218487496163564,-0.2218487496163564,-1.1939466469446158,20,cytokine
BSK_CASM3C_uPAR_down,"Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1,PLAUR,"plasminogen activator, urokinase receptor",https://www.ncbi.nlm.nih.gov/gene/5329,,,Active,0.8776330847094571,8.202997264925337,10,1,0.0356631060723,0.7313698,log10_fold_induction,1,0.1069893182169,,1,1,0.7477567836301718,20,cytokine
BSK_CASM3C_VCAM1_down,"Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.9799291514595586,11.361735894035018,5.000000000000001,0.6989700043360189,0.028749396529979997,0.81660765,log10_fold_induction,1,0.08624818958993999,,0.6989700043360189,0.6989700043360189,0.5910277347737978,20,cell adhesion molecules
BSK_hDFCGF_CollagenIII_down,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",NP_000081.1,COL3A1,"collagen, type III, alpha 1",https://www.ncbi.nlm.nih.gov/gene/1281,,,Active,0.6501685199524443,4.593415162103957,5.000000000000001,0.6989700043360189,0.047181200117099996,0.5418071,log10_fold_induction,1.60205999132796,0.14154360035129998,"[""Less than 50% efficacy""]",0.6989700043360189,0.6989700043360189,0.6289242431502704,20,cell adhesion molecules
BSK_hDFCGF_IL8_down,"Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,1.1939658346706694,15.078896762404316,20.000000000000004,1.3010299956639813,0.008495260327134,1.189091,log10_fold_induction,1.60205999132796,0.07918124604762482,,1.3010299956639813,1.3010299956639813,1.056635595199821,20,cytokine
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2,CXCL10,chemokine (C-X-C motif) ligand 10,https://www.ncbi.nlm.nih.gov/gene/3627,,,Active,0.9952897593572089,12.304849787458766,10,1,0.0269619913164,1.0038707,log10_fold_induction,1.60205999132796,0.0808859739492,,1,1,0.7287869879668017,20,cytokine
BSK_hDFCGF_MCSF_down,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3,CSF1,colony stimulating factor 1 (macrophage),https://www.ncbi.nlm.nih.gov/gene/1435,,,Active,0.523053490500737,4.891640691116295,10,1,0.0356426758443,0.5172135,log10_fold_induction,1.60205999132796,0.10692802753289998,"[""Less than 50% efficacy""]",1,1,0.689409142256221,20,cytokine
BSK_hDFCGF_MIG_down,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,1.4627729999665273,18.47373049783429,10,1,0.015977820005069997,1.2189775,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.9043708280925278,20,cytokine
BSK_hDFCGF_MMP1_down,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),https://www.ncbi.nlm.nih.gov/gene/4312,,,Active,0.9292809560971046,11.689335636717363,20.000000000000004,1.3010299956639813,0.026499394689809996,0.7744008,log10_fold_induction,1.30102999566398,0.07949818406942999,,1.3010299956639813,1.3010299956639813,1.0610197173039637,20,protease
BSK_hDFCGF_PAI1_down,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",https://www.ncbi.nlm.nih.gov/gene/5054,,,Active,0.6525806774707755,3.939804848252825,10,1,0.055212605920499994,0.60394776,log10_fold_induction,1.30102999566398,0.1656378177615,,1,1,0.4104936989552589,20,cytokine
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.0763707199789052,7.943485398796756,5.000000000000001,0.6989700043360189,0.0451678604517,0.8969756,log10_fold_induction,1,0.1355035813551,"[""Cell viability assay fit with gnls winning model""]",0.6989700043360189,0.6989700043360189,0.34597184622587507,20,cell cycle
BSK_hDFCGF_SRB_down,"Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.5027754108004896,6.349677933813865,20.000000000000004,1.3010299956639813,0.024374730148650003,1.1232815,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Noisy data"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,1.0048531965911338,20,cell cycle
BSK_hDFCGF_TIMP1_down,"Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",NP_003245.1,TIMP1,TIMP metallopeptidase inhibitor 1,https://www.ncbi.nlm.nih.gov/gene/7076,,,Active,0.34632967246442026,2.581034745864889,20.000000000000004,1.3010299956639813,0.0447274971171,0.34530136,log10_fold_induction,1.30102999566398,0.1341824913513,"[""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.9459295877978009,20,protease inhibitor
BSK_hDFCGF_VCAM1_down,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.8207394485924734,5.8085102911792585,5.000000000000001,0.6989700043360189,0.04709982465089999,0.8210125,log10_fold_induction,1.60205999132796,0.14129947395269998,,0.6989700043360189,0.6989700043360189,0.5384440239605479,20,cell adhesion molecules
BSK_KF3CT_ICAM1_down,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_000192.2,ICAM1,intercellular adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/3383,,,Active,0.5677945199948432,7.1708207225399585,10,1,0.02073805097175,0.4731621,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy""]",1,1,0.7125584656164099,20,cell adhesion molecules
BSK_KF3CT_IL1a_down,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3,IL1A,"interleukin 1, alpha",https://www.ncbi.nlm.nih.gov/gene/3552,,,Active,0.4917374617131617,5.728239708130143,10,1,0.0286148093637,0.6426267,log10_fold_induction,1.60205999132796,0.08584442809109999,"[""Less than 50% efficacy""]",1,1,0.6945568856338936,20,cytokine
BSK_KF3CT_IP10_down,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2,CXCL10,chemokine (C-X-C motif) ligand 10,https://www.ncbi.nlm.nih.gov/gene/3627,,,Active,1.0342878060372285,13.062282518453166,10,1,0.0138351257877,1.0366457,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.7482403451204542,20,cytokine
BSK_KF3CT_MCP1_down,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.28966316632512845,2.520907474054201,10,1,0.0383014409568,0.31793046,log10_fold_induction,1.60205999132796,0.1149043228704,"[""Less than 50% efficacy""]",1,1,0.8253607174368761,20,cytokine
BSK_KF3CT_MMP9_down,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",AAM97934.1,MMP9,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",https://www.ncbi.nlm.nih.gov/gene/4318,,,Active,0.9639793812863338,11.51662342279106,10,1,0.027901099882530003,1.00101,log10_fold_induction,1.60205999132796,0.08370329964759,,1,1,0.8319685891892153,20,protease
BSK_KF3CT_SRB_down,"Data from the assay component BSK_KF3CT_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_KF3CT_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.6145784399977258,7.761666690974752,10,1,0.00501083847705,0.5121487,log10_fold_induction,1,0.07918124604762482,"[""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model""]",1,1,0.7355850717343513,20,cell cycle
BSK_KF3CT_TGFb1_down,"Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",P01137.2,TGFB1,"transforming growth factor, beta 1",https://www.ncbi.nlm.nih.gov/gene/7040,,,Active,0.6572415076619877,6.156105538,10,1,0.0355875157113,0.6579221,log10_fold_induction,1.60205999132796,0.10676254713389999,,1,1,0.631032992826823,20,growth factor
BSK_KF3CT_TIMP2_down,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",,TIMP2,TIMP metallopeptidase inhibitor 2,https://www.ncbi.nlm.nih.gov/gene/7077,,,Active,0.8998944589898765,9.788755020612232,10,1,0.030643817220029995,0.8846066,log10_fold_induction,1.60205999132796,0.09193145166008998,,1,1,0.7443081777864977,20,protease inhibitor
BSK_KF3CT_uPA_down,"Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_002649.1,PLAU,"plasminogen activator, urokinase",https://www.ncbi.nlm.nih.gov/gene/5328,,,Active,0.7251322643483249,9.1578789239081,10,1,0.020151273081261,0.7275396,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.9094008698374255,20,protease
BSK_LPS_CD40_down,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1,CD40,"CD40 molecule, TNF receptor superfamily member 5",https://www.ncbi.nlm.nih.gov/gene/958,,,Active,0.34936151038533075,2.5310796183270674,10,1,0.0460095510042,0.34746405,log10_fold_induction,1.30102999566398,0.13802865301259998,"[""Less than 50% efficacy""]",1,1,0.8983663609489058,20,cytokine
BSK_LPS_Eselectin_down,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2,SELE,selectin E,https://www.ncbi.nlm.nih.gov/gene/6401,,,Active,0.8063840208963606,10.184027925139599,10,1,0.0245760564798,0.80460185,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.8617679938896201,20,cell adhesion molecules
BSK_LPS_IL1a_down,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3,IL1A,"interleukin 1, alpha",https://www.ncbi.nlm.nih.gov/gene/3552,,,Active,0.37249089048224,3.0182515204696267,10,1,0.041137602124499996,0.3733718,log10_fold_induction,1.60205999132796,0.1234128063735,"[""Less than 50% efficacy""]",1,1,0.8848894453052587,20,cytokine
BSK_LPS_IL8_down,"Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.6094677644472136,6.866750814313126,20.000000000000004,1.3010299956639813,0.029585451252860995,0.56166685,log10_fold_induction,1.30102999566398,0.08875635375858298,"[""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,1.0473406695587861,20,cytokine
BSK_LPS_MCP1_down,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.8753255399955582,9.761291461627566,10,1,0.029891042711459998,0.72943795,log10_fold_induction,1.30102999566398,0.08967312813438,,1,1,0.9234613020798977,20,cytokine
BSK_LPS_MCSF_down,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3,CSF1,colony stimulating factor 1 (macrophage),https://www.ncbi.nlm.nih.gov/gene/1435,,,Active,0.43837915389699655,4.206526546286418,10,1,0.0347380155633,0.3913801,log10_fold_induction,1.30102999566398,0.1042140466899,"[""Less than 50% efficacy""]",1,1,0.79895690313205,20,cytokine
BSK_LPS_PGE2_down,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000947.2,PTGER2,"prostaglandin E receptor 2 (subtype EP2), 53kDa",https://www.ncbi.nlm.nih.gov/gene/5732,,,Active,0.28189218501812363,1.9996690346494377,20.000000000000004,1.3010299956639813,0.04698980683529999,0.2807443,log10_fold_induction,1.60205999132796,0.14096942050589997,"[""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.9161242196728636,20,gpcr
BSK_LPS_SRB_down,"Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_LPS_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.1245627909802416,14.202388155193407,10,1,0.018219059086199998,0.94635177,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Cell viability assay fit with gnls winning model""]",1,1,0.9587290967184184,20,cell cycle
BSK_LPS_TissueFactor_down,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1,F3,"coagulation factor III (thromboplastin, tissue factor)",https://www.ncbi.nlm.nih.gov/gene/2152,,,Active,0.3568130690201651,2.9438780537407836,10,1,0.0404017039776,0.35809326,log10_fold_induction,1.30102999566398,0.1212051119328,"[""Less than 50% efficacy""]",1,1,0.8749634361862139,20,cytokine
BSK_LPS_TNFa_down,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_000585.2,TNF,tumor necrosis factor,https://www.ncbi.nlm.nih.gov/gene/7124,,,Active,2.085030137681529,15.312898985380283,20.000000000000004,1.3010299956639813,0.04538722854225,2.0741055,log10_fold_induction,1.60205999132796,0.13616168562675,,1.3010299956639813,1.3010299956639813,1.1229595696930612,20,cytokine
BSK_LPS_VCAM1_down,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.9755329199396798,12.320252188920216,5.000000000000001,0.6989700043360189,0.0224178208338,0.8129441,log10_fold_induction,1.30102999566398,0.07918124604762482,,0.6989700043360189,0.6989700043360189,0.7209424628276588,20,cell adhesion molecules
BSK_SAg_CD38_down,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",NP_001766.2,CD38,CD38 molecule,https://www.ncbi.nlm.nih.gov/gene/952,,,Active,0.6432298779565345,8.123512953681654,10,1,0.0243080164845,0.5360249,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy""]",1,1,0.7084290895014362,20,cytokine
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1,CD40,"CD40 molecule, TNF receptor superfamily member 5",https://www.ncbi.nlm.nih.gov/gene/958,,,Active,0.5602802554886679,5.619743956939614,10,1,0.0332328459435,0.5474875,log10_fold_induction,1.30102999566398,0.09969853783049999,"[""Less than 50% efficacy""]",1,1,0.7200157286064924,20,cytokine
BSK_SAg_CD69_down,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001772.1,CD69,CD69 molecule,https://www.ncbi.nlm.nih.gov/gene/969,,,Active,0.6227326501219438,5.881546738559999,10,1,0.03529302057225,0.5603095,log10_fold_induction,1.30102999566398,0.10587906171674999,"[""Less than 50% efficacy""]",1,1,0.7535093274325229,20,cytokine
BSK_SAg_Eselectin_down,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2,SELE,selectin E,https://www.ncbi.nlm.nih.gov/gene/6401,,,Active,0.8944027510221676,7.793920401008084,10,1,0.038252154885,0.74533564,log10_fold_induction,1.30102999566398,0.114756464655,,1,1,0.739740994148695,20,cell adhesion molecules
BSK_SAg_IL8_down,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.46961125330471676,3.1262478924890593,10,1,0.050071872038999994,0.47366232,log10_fold_induction,1.60205999132796,0.150215616117,"[""Less than 50% efficacy""]",1,1,0.7783343191950608,20,cytokine
BSK_SAg_MCP1_down,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.8248838210456513,8.66517782437616,10,1,0.031731751991099996,0.6874032,log10_fold_induction,1.30102999566398,0.09519525597329999,,1,1,0.8267360453429315,20,cytokine
BSK_SAg_MIG_down,"Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,1.3444400394674607,16.979273585298543,20.000000000000004,1.3010299956639813,0.00921114872622,1.1203667,log10_fold_induction,1.30102999566398,0.07918124604762482,,1.3010299956639813,1.3010299956639813,1.0433022435999368,20,cytokine
BSK_SAg_PBMCCytotoxicity_down,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,0.8351789302740549,10.547686124713461,5.000000000000001,0.6989700043360189,0.0217234984974,0.80492586,log10_fold_induction,1.60205999132796,0.07918124604762482,,0.6989700043360189,0.6989700043360189,0.6114405760446702,20,cell cycle
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.0771954334550355,9.000649091214747,5.000000000000001,0.6989700043360189,0.0398932500141,1.0762302,log10_fold_induction,1.60205999132796,0.1196797500423,,0.6989700043360189,0.6989700043360189,0.6175447850793425,20,cell cycle
BSK_SAg_SRB_down,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.0339815070963732,13.058414191593657,10,1,0.017346765986949,0.8638015,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Cell viability assay fit with gnls winning model""]",1,1,0.8797711902554329,20,cell cycle
CCTE_GLTED_hDIO1_dn,"Data from the assay component CCTE_GLTED_hDIO1 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO1_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 1'.",,DIO1,iodothyronine deiodinase 1,https://www.ncbi.nlm.nih.gov/gene/1733,,,Active,81.97960704702021,4.098980352351011,100.23224715499329,2.0010074671239675,5.074688733372146,62.5465376,percent_activity,2.30102999566398,20,,1.6826434092415807,1.5849486432049247,1.382552914071299,20,deiodinase
CCTE_GLTED_hDIO2_dn,"Data from the assay component CCTE_GLTED_hDIO2 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO2_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 2'.",,DIO2,iodothyronine deiodinase 2,https://www.ncbi.nlm.nih.gov/gene/1734,,,Active,96.69602957038443,4.834801478519221,23.79410756540206,1.3764694205577797,4.347339401816814,86.79173916,percent_activity,2.30102999566398,20,,0.7746539015012135,0.5443384010510315,0.3926836395974235,20,deiodinase
CCTE_GLTED_hDIO3_dn,"Data from the assay component CCTE_GLTED_hDIO3 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO3_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 3'.",,DIO3,iodothyronine deiodinase 3,https://www.ncbi.nlm.nih.gov/gene/1735,,,Active,97.55575786403975,4.877787893201988,3.1261973310486293,0.49501638797642167,4.524033444680399,98.8700565,percent_activity,2.30102999566398,20,,-0.15588096373968707,-0.38033236845568485,-0.5602516266159446,20,deiodinase
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,98.9285071662315,4.946425358311575,4.613176516442401,0.664000072568431,1.53481347591287,99.1933020077197,percent_activity,0.903089986991944,20,"[""Noisy data"",""Noisy data""]",0.589474585876562,0.500069365137114,0.544719758798168,20,malformation
CPHEA_Stoker_NIS_Cytotoxicity," Data from the assay component CPHEA_Stoker_NIS_Cytotoxicity was analyzed at the endpoint, CPHEA_Stoker_NIS_Cytotoxicity, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,50.486076305353954,1.0309748666220475,0.23935007923588966,-0.6209664244105517,16.323086669341674,52.73478388298838,percent_activity,2,48.96926000802502,"[""Borderline active"",""Only highest conc above baseline, active""]",4.409002092046318,4.409002092046318,-3.801774789028434,20,cell cycle
CPHEA_Stoker_NIS_Inhibition_RAIU,"Data from the assay component CPHEA_Stoker_NIS_Inhibition_RAIU was analyzed at the endpoint, CPHEA_Stoker_NIS_Inhibition_RAIU, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Measures of radioactive substrate uptake for loss-of-signal activity can be used to understand the effects on transporter function at the pathway level as they relate to the sodium-iodide symporter, gene SLC5A5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is sodium-iodide symporter (NIS).",,SLC5A5,solute carrier family 5 member 5,https://www.ncbi.nlm.nih.gov/gene/6528,,,Active,82.37688191189571,1.3689941906863703,11.610347323749904,1.0648452118601752,20.057762716678525,81.24053564535764,percent_activity,2,60.173288150035575,"[""Only highest conc above baseline, active""]",1.1356809100842578,1.1356809100842578,0.9087309320421849,20,transporter
LTEA_HepaRG_ABCC2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000383.1,ABCC2,"ATP-binding cassette, sub-family C (CFTR/MRP), member 2",https://www.ncbi.nlm.nih.gov/gene/1244,,,Active,0.7625411945743,1.776803490541974,80.04673819203694,1.90334363963994,0.143054873284778,0.444241676166665,log2_fold_induction,2,0.429164619854334,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.95692444480532,1.95692444480532,1.4372152177243,20,transporter
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1543,"[57,57]",,Active,1.47119714056452,1.633609459188914,60.272149867434216,1.78011668273905,0.300193564683644,1.02684874100001,log2_fold_induction,2,0.900580694050932,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.91920632387569,1.91920632387569,1.11039039986273,20,cyp
NVS_ENZ_hDUSP3,"Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDUSP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"".",NP_004081.1,DUSP3,dual specificity phosphatase 3,https://www.ncbi.nlm.nih.gov/gene/1845,,,Active,79.3791748518794,3.96895874259397,20.299155596646106,1.30747797252679,1.28111925368239,66.1493123772102,percent_activity,1.69897000433602,20,,1.03120593673843,0.551365530930602,0.749652753036086,20,phosphatase
NVS_ENZ_hPTPRC,"Data from the assay component NVS_ENZ_hPTPRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"".",NP_002829.3,PTPRC,"protein tyrosine phosphatase, receptor type, C",https://www.ncbi.nlm.nih.gov/gene/5788,,,Active,57.5943396224592,2.87971698112296,14.958440974427193,1.17488633206548,1.30438307034025,47.9952830188679,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.936418352127602,0.185407779695369,0.344669114084556,20,phosphatase
NVS_NR_hER,"Data from the assay component NVS_NR_hER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hER, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,30,67,112,167,200,29,165,53,52,167,112,30,67]",[1181],Active,24.9198214950038,1.0215710472465038,0.10962874537178359,-0.960075556075049,4.06560424132541,30.4784020064923,percent_activity,0.778151250383644,24.3936254479525,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",-0.321668945174765,-0.967104180403272,-1.32571039620015,20,nuclear receptor
NVS_NR_hPXR,"Data from the assay component NVS_NR_hPXR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPXR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,85.4794096443155,2.2512932849093517,40.95000093055204,1.61225391596539,6.32817073170732,71.2328767123288,percent_activity,1.69897000433602,37.9690243902439,"[""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.60008402671541,1.54420530614835,1.49297360218969,20,nuclear receptor
OT_AR_ARSRC1_0480,"Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1,"AR | SRC","androgen receptor , SRC proto-oncogene, non-receptor tyrosine kinase","https://www.ncbi.nlm.nih.gov/gene/367 , https://www.ncbi.nlm.nih.gov/gene/6714",,,Active,56.0494104687612,2.80247052343806,10.650272093698188,1.02736070329421,2.45637869822485,72.9113924050633,percent_activity,1.47712125471966,20,,0.995376924443204,0.924867823289637,0.908079429491279,20,nuclear receptor
OT_AR_ARSRC1_0960,"Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1,"AR | SRC","androgen receptor , SRC proto-oncogene, non-receptor tyrosine kinase","https://www.ncbi.nlm.nih.gov/gene/367 , https://www.ncbi.nlm.nih.gov/gene/6714",,,Active,78.2638408809354,3.9131920440467702,13.206913534476614,1.12080133452872,1.6382320441989,67.6635831709751,percent_activity,1.47712125471966,20,,0.91584274317705,0.602677817935303,0.699627328481489,20,nuclear receptor
OT_ER_ERaERb_1440,"Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".","NP_000116.2|NP_001428.1","ESR1 | ESR2","estrogen receptor 1 , estrogen receptor 2 (ER beta)","https://www.ncbi.nlm.nih.gov/gene/2099 , https://www.ncbi.nlm.nih.gov/gene/2100",,,Active,28.4534001456128,1.42267000728064,6.614842742655458,0.820519523987045,1.91268599454975,20.0546407738315,percent_activity,1,20,"[""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",0.984223387368555,0.558962491562872,0.402835611577729,20,nuclear receptor
OT_ER_ERbERb_1440,"Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001428.1,ESR2,estrogen receptor 2 (ER beta),https://www.ncbi.nlm.nih.gov/gene/2100,,,Active,23.5274349980302,1.1763717499015098,3.378250159049424,0.528691805883946,1.48426296250401,23.3535291817525,percent_activity,1,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",0.624393362060701,0.448451750592101,0.407505486327834,20,nuclear receptor
TOX21_AP1_BLA_Agonist_ch1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,32.1876595019982,1.6093829750999098,43.60880613608547,1.63957419729926,2.57591984669775,23.4079191452,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.77824502619466,1.31698977886845,1.02442011514892,20,channel 1
TOX21_AP1_BLA_Agonist_ch2,"Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,70.5335390562263,3.3101841148188758,46.661963139502824,1.6689630062691,3.55134017774949,57.5611126461,percent_activity,1.90308998699194,21.3080410664969,,1.52714709386536,1.37656765060585,1.2968248516943,20,channel 2
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1,"JUN | FOS|JUN","jun proto-oncogene , FBJ murine osteosarcoma viral oncogene homolog|jun proto-oncogene","https://www.ncbi.nlm.nih.gov/gene/3725 , https://www.ncbi.nlm.nih.gov/gene/4029",,,Active,90.8368988347517,4.541844941737585,55.11705387652659,1.74128599555845,2.7369041511147,63.7621186943,percent_activity,1.90308998699194,20,,1.51577998376022,1.32957618547697,1.34948729350335,20,dna binding
TOX21_AR_BLA_Antagonist_ratio,"Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,"[307,19,23,111,187,117,307,111,19,23,187,117]",,Active,45.1288100055126,1.7295740591253976,70.0947300615493,1.84568536759258,4.34874025461246,32.2463609974,percent_activity,1.90308998699194,26.0924415276748,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.86280169575273,1.79683727840696,1.72640504605663,20,nuclear receptor
TOX21_ARE_BLA_Agonist_ch1,"Data from the assay component TOX21_ARE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,70.7136064235319,3.535680321176595,28.53234605600631,1.45533748274324,2.85455403754395,58.8779097323,percent_activity,1.95424250943932,20,,1.08461442895713,0.665642392850757,0.579899442926328,20,channel 1
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,31.8087281377546,1.59043640688773,2.431586201334194,0.385889670202854,2.50978290890691,25.2182102275,percent_activity,0.903089986991944,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.604938979484123,-0.100863608739774,-0.527578933197079,20,dna binding
TOX21_ARE_BLA_agonist_viability,"TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,73.4224022228976,2.480656983944042,10.752196818283853,1.03149720551558,4.93299441089742,70.488809846,percent_activity,1.95424250943932,29.5979664653845,,0.964221479519958,0.795539338918271,0.654872517560112,20,cell cycle
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,80.3048337026935,2.499634032614003,52.66173268585104,1.7214951442407,5.35443940025589,65.8423445801,percent_activity,1.95424250943932,32.1266364015353,,1.65373632640668,1.48971731439199,1.35408747508043,20,nuclear receptor
TOX21_Aromatase_Inhibition,"Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.",NP_000094.2,CYP19A1,"cytochrome P450, family 19, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1588,"[122,123,7,153,25,122,123,7,153,25]",[964],Active,58.5870455235856,2.1831416397204007,34.6702188401091,1.53995658295296,4.47268624701549,59.3786178839,percent_activity,1.95424250943932,26.8361174820929,,1.52927546362027,1.4628644350712,1.40040519803485,20,cyp
TOX21_CASP3_CHO,"The assay component endpoint  TOX21_CASP3_CHO was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_CHO assay is a homogeneous, luminescent assay that measures caspase-3 activity following chemical treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.",NP_116786.1,CASP3,"caspase 3, apoptosis-related cysteine peptidase",https://www.ncbi.nlm.nih.gov/gene/836,,,Active,77.2643358868551,3.8632167943427547,37.75903023031028,1.57702083173214,0.87784491667383,75.7774326387,percent_activity,1.95424250943932,20,,1.47316972264122,1.24686918952707,1.36010450297874,20,apoptosis
TOX21_CASP3_CHO_viability,"The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,78.5399947238172,3.92699973619086,79.3434225533677,1.89951093024429,2.57636017956492,46.608181947,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.72517494590735,1.53995208850001,1.54284129744375,20,cell cycle
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,98.5931431883735,4.107941831961086,0.7958399213913095,-0.0991742793073763,4.0001030208237,99.9055969546,percent_activity,1.30102999566398,24.0006181249422,,-0.250744921632572,-0.363333990496285,-0.392865882201272,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,"RAD54L | XRCC6P1","RAD54 like (S. cerevisiae) , X-ray repair cross complementing 6 pseudogene 1","https://www.ncbi.nlm.nih.gov/gene/8438 , https://www.ncbi.nlm.nih.gov/gene/387703",,,Active,108.836890355047,5.045894730487485,0.7904146697403525,-0.102145008035605,3.59489896137582,109.9592877755,percent_activity,1.60205999132796,21.5693937682549,,-0.323424456390441,-0.45160844965766,-0.450001984590601,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,REV3L,"REV3 like, DNA directed polymerase zeta catalytic subunit",https://www.ncbi.nlm.nih.gov/gene/5980,,,Active,106.699503069504,4.072186889843947,0.9972340308137576,-0.00120290952801967,4.36700254498032,107.7061778205,percent_activity,1.30102999566398,26.2020152698819,,-0.176972057241749,-0.309134560568551,-0.345294011315567,20,cell cycle
TOX21_ELG1_LUC_Agonist_viability,"TOX21_ELG1_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,58.7522298220201,1.8194299451552085,21.727999006758267,1.33701973274771,5.38192653679485,56.8513603271,percent_activity,1.95424250943932,32.2915592207691,,1.37858161533205,1.13450814928877,0.878458573893079,20,cell cycle
TOX21_ESRE_BLA_ch1,"Data from the assay component TOX21_ESRE_BLA_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,61.4601177683142,2.9850272938231788,76.84616871160439,1.88562221993093,3.43157765511288,32.2498468908,percent_activity,1.90308998699194,20.5894659306773,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.84836504570069,1.79849203392019,1.76622537204235,20,channel 1
TOX21_ESRE_BLA_viability,"TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,87.807520528029,1.971596213549316,35.4849197411059,1.55004382728974,7.42270991093352,59.73043092,percent_activity,1.90308998699194,44.5362594656011,,1.56809011414561,0.873976225054415,0.173962830598954,20,cell cycle
TOX21_GR_BLA_Antagonist_ratio,"Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand gene activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000167.1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",https://www.ncbi.nlm.nih.gov/gene/2908,"[64,66,214,71,14,318,64,214,66,71,14,318]",,Active,79.0025086964598,2.075548956073137,35.407961041760494,1.54910091874321,6.34390470252021,51.8355527489,percent_activity,1.90308998699194,38.0634282151213,,1.51658403869899,1.03666551168955,0.568107886453433,20,nuclear receptor
TOX21_HRE_BLA_Agonist_ch1,"Data from the assay component TOX21_HRE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,67.6925149384818,3.3846257469240904,13.888424955252997,1.14265299649154,2.28898316931438,68.0916606006,percent_activity,1.90308998699194,20,,1.09547546686366,1.02423770630411,1.02337268019486,20,channel 1
TOX21_HRE_BLA_Agonist_ratio,"Data from the assay component TOX21_HRE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is hypoxia-response element.",NP_001521.1,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",https://www.ncbi.nlm.nih.gov/gene/3091,,,Active,49.4729374279509,2.4736468713975452,26.97919349727641,1.43102896294457,0.3624938875215,49.2476480965,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.40997978464135,1.2249923512139,1.3117486492572,20,dna binding
TOX21_HRE_BLA_Agonist_viability,"TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,98.663982487841,4.93319912439205,11.671416833361638,1.06712357974384,3.0508964104962,98.2386055265,percent_activity,1.90308998699194,20,,0.788749387931838,0.603594446722362,0.620484986256992,20,cell cycle
TOX21_HSE_BLA_agonist_ch2,"Data from the assay component TOX21_HSE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,38.9037230033689,1.945186150168445,31.380400833545455,1.49665848669149,0.96226530123801,39.6708903603,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.49980020872607,1.35600329557274,1.37420586697013,20,channel 2
TOX21_HSE_BLA_agonist_ratio,"Data from the assay component TOX21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_HSE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is heat shock protein.",NP_005517.1,HSF1,heat shock transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/3297,,,Active,35.4000087336363,1.770000436681815,31.576242390359468,1.49936044719768,0.91844270028357,36.0520108091,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.51803296785326,1.32274411472076,1.34238515458384,20,dna binding
TOX21_MMP_ratio_down,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",, , , ,,,Active,40.6528897818252,1.051453531293921,61.840337079432935,1.79127184816995,6.44391923052108,38.8067890606,percent_activity,1.95424250943932,38.6635153831265,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.95234531431071,1.78595447141734,1.67199126463907,20,cell morphology
TOX21_p53_BLA_p1_ch1,"Data from the assay component TOX21_p53_BLA_p1_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,21.4076512008899,1.0703825600444952,17.982468994464913,1.25484932015901,3.00976293237186,22.7134914701,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.57897789039538,1.21631795746152,0.986486731421024,20,channel 1
TOX21_p53_BLA_p1_ratio,"Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,29.105452223623,1.45527261118115,52.449661854637895,1.71974269262227,1.19928273802848,23.5779674846,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Borderline active"",""Less than 50% efficacy""]",1.85571130164643,1.38129110038791,1.34006398304115,20,dna binding
TOX21_p53_BLA_p1_viability,"TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,67.4763836207464,1.6083956875817962,56.460280937742674,1.75174303479935,6.99210027956454,66.2485996459,percent_activity,1.95424250943932,41.9526016773872,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.7787197962509,1.70852738813216,1.63246260027338,20,cell cycle
TOX21_p53_BLA_p3_ch1,"Data from the assay component TOX21_p53_BLA_p3_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,68.4871553920089,3.3341776157996397,3.379363799351781,0.528834947485551,3.42349065166122,75.6837011489,percent_activity,1.95424250943932,20.5409439099673,,0.404128582849224,0.273599309613028,0.205582689692387,20,channel 1
TOX21_p53_BLA_p3_ratio,"Data from the assay component TOX21_p53_BLA_p3_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_p53_BLA_p3_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter,  gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,53.9391124612612,2.6969556230630602,5.067166649840969,0.704765187676538,0.8227628069073,52.4861836799,percent_activity,1.95424250943932,20,,0.512704021316577,-0.398382261169723,-0.0932168827586519,20,dna binding
TOX21_p53_BLA_p3_viability,"TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,98.7632282859614,3.2767342778069675,3.6018035302342795,0.556520019404606,5.02345831309728,100.3979206511,percent_activity,1.95424250943932,30.1407498785837,,0.420764915622241,0.273634730868186,0.193970859599066,20,cell cycle
TOX21_PPARg_BLA_Antagonist_ch1,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,57.1721273175738,2.1140172956148837,0.5499109175861733,-0.259707658022497,4.5073840720356,66.0579532993,percent_activity,0.845098040014257,27.0443044322136,,-0.278591765636006,-0.464664942566361,-0.643995890359204,20,channel 1
TOX21_PPARg_BLA_Antagonist_ch2,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,188.618218699647,2.0550273479217482,6.992292906007913,0.84461961253232,15.2972999678404,179.1863961014,percent_activity,1.90308998699194,91.7837998070424,,0.830827690024771,0.552481501604945,0.278895805717597,20,channel 2
TOX21_PPARg_BLA_antagonist_ratio,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,"[34,36,58,72,163,72,36,58,34,163]",,Active,98.325108194917,2.7326066742942428,0.8263004974165352,-0.0828619858067998,5.9970277415496,99.3770842666,percent_activity,1.30102999566398,35.9821664492976,,-0.131894417014896,-0.216348981769427,-0.278877207943101,20,nuclear receptor
TOX21_PPARg_BLA_antagonist_viability,"TOX21_PPARg_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,100.822945708655,1.8402573910899627,1.8430955736241417,0.265547856120532,9.1312358619699,101.1774519541,percent_activity,1.47712125471966,54.7874151718194,,0.332284968632816,-0.112530353020718,-0.576962559191192,20,cell cycle
TOX21_RAR_LUC_Agonist,"Data from the assay component TOX21_RAR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_000955.1,RARA,"retinoic acid receptor, alpha",https://www.ncbi.nlm.nih.gov/gene/5914,,,Active,43.4984051490488,2.17492025745244,68.54443229914297,1.83597218385257,0.83869932137985,32.8986538599,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.81903660081002,1.54281153326928,1.60513338223696,20,nuclear receptor
TOX21_RORg_LUC_CHO_Antagonist,"Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_005051.2,RORC,RAR-related orphan receptor C,https://www.ncbi.nlm.nih.gov/gene/6097,,,Active,109.764020906398,2.1065827215497,78.43207469769742,1.89449370318865,8.68420845631059,80.8674598108,percent_activity,1.95424250943932,52.1052507378635,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.88899571759463,1.83112706724177,1.77521338950828,20,nuclear receptor
TOX21_RORg_LUC_CHO_Antagonist_viability,"TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,88.7011471921684,4.43505735960842,7.068608159900567,0.849333907717377,3.0881472477345,89.0904434389,percent_activity,1.60205999132796,20,,0.64385885383468,0.491547823491918,0.483480960439832,20,cell cycle
TOX21_RT_HEK293_FLO_08hr_viability,"TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,32.9910284876039,1.4008544367051068,0.8385368509394522,-0.0764778468229679,3.92510785122456,27.4925237418,percent_activity,0,23.5506471073474,"[""Cell viability assay fit with gnls winning model"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy""]",-0.0268511836697656,-0.108438424004961,-0.195758160505641,20,cell cycle
TOX21_RT_HEK293_FLO_16hr_viability,"TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,26.8589718763981,1.0710696117713494,36.811678382057934,1.56598561900736,4.17946253309319,25.3694370025,percent_activity,1.90308998699194,25.0767751985591,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.88018109549152,1.55019287346656,1.30489140359534,20,cell cycle
TOX21_RT_HEK293_FLO_24hr_viability,"TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,61.0635604749969,2.2732048348777423,28.466780340643894,1.45433835020409,4.47705368342379,60.8054809838,percent_activity,1.90308998699194,26.8623221005427,,1.43450997651032,1.35041462619852,1.27396287383006,20,cell cycle
TOX21_RT_HEK293_FLO_32hr_viability,"TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,101.549668710526,3.5719296052750376,28.360307527900183,1.45271093585327,4.73831980341741,101.3660317558,percent_activity,1.90308998699194,28.4299188205045,,1.38538485129321,1.32332278697985,1.29611376253412,20,cell cycle
TOX21_RT_HEK293_FLO_40hr_viability,"TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,152.289859351969,5.336390202462697,28.396871592372953,1.45327049761724,4.75633195144065,151.9233084073,percent_activity,1.90308998699194,28.5379917086439,,1.34371720352897,1.2838063798288,1.28918988571662,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,46.2396553720384,1.918160293232958,29.94507788433548,1.47632544698086,4.0177086637968,46.0299327635,percent_activity,1.90308998699194,24.1062519827808,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.48096063363466,1.41973103147579,1.35704513148674,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,53.6874462210109,2.188183669305027,30.433027381745198,1.4833451567548,4.08919407864135,53.4453651166,percent_activity,1.90308998699194,24.5351644718481,,1.47398470933049,1.41728894512541,1.36406484249305,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,60.2334565999127,2.39759972424611,30.46709471437585,1.48383104268109,4.18706647811088,60.0037806225,percent_activity,1.90308998699194,25.1223988686653,,1.46565819131147,1.41142671482524,1.36455072516904,20,cell cycle
TOX21_RT_HEK293_GLO_40hr_viability,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,65.3704629021935,2.624753328460251,30.05151246105449,1.47786633447388,4.15089564121323,65.2268060075,percent_activity,1.90308998699194,24.9053738472794,,1.45151780160323,1.3993237118485,1.35858555245387,20,cell cycle
TOX21_RT_HEPG2_FLO_24hr_viability,"TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,39.4430257353394,1.4379499507235751,25.407266452098156,1.40495794216054,4.57167345723585,32.8691881154,percent_activity,1.47712125471966,27.4300407434151,"[""Hit-call potentially confounded by overfitting"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Cell viability assay fit with gnls winning model"",""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.44977988196437,1.37080673456429,1.28567762839946,20,cell cycle
TOX21_RT_HEPG2_FLO_32hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,70.401316935463,2.404353915880464,25.34657127657402,1.40391921903915,4.88012714978376,58.6677641227,percent_activity,1.47712125471966,29.2807628987026,"[""Cell viability assay fit with gnls winning model"",""Cell viability assay fit with gnls winning model""]",1.3854846478411,1.33132201166695,1.2846389053538,20,cell cycle
TOX21_RT_HEPG2_FLO_40hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,64.3006349780161,2.387821539667629,26.661910945724827,1.425891273489,4.48809608184861,87.0827713636,percent_activity,1.47712125471966,26.9285764910917,,1.40809957052623,1.35376740688972,1.30661095978123,20,cell cycle
TOX21_SHH_3T3_GLI3_Antagonist,"Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",,SHH,sonic hedgehog,https://www.ncbi.nlm.nih.gov/gene/6469,,,Active,74.1352857208255,1.6771839649851437,48.78506976088914,1.68828693035185,7.36703975915985,55.2056793314,percent_activity,1.95424250943932,44.2022385549591,,1.80047009487382,1.44186234577199,1.05595285170086,20,dna binding
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2","THRA | THRB","thyroid hormone receptor, alpha , thyroid hormone receptor, beta","https://www.ncbi.nlm.nih.gov/gene/7067 , https://www.ncbi.nlm.nih.gov/gene/7068",,,Active,108.892667188438,4.853318896521606,56.12261889196763,1.74913792863916,3.73945711206963,87.2169573173,percent_activity,1.95424250943932,22.4367426724178,,1.53101187659008,1.3991999923315,1.39384135494694,20,nuclear receptor
TOX21_TR_LUC_GH3_Antagonist_viability,"TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,48.8480142737388,1.218904386233785,57.991872926840365,1.76336713510891,6.67922423139783,49.0404444669,percent_activity,1.95424250943932,40.075345388387,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.84583538432701,1.74365448031142,1.64408673872303,20,cell cycle
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,120.733023879224,3.1790595333864435,57.816307915746975,1.76205035466404,12.6591971211703,91.0651012499016,percent_activity,2,37.9775913635109,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.58227785991625,1.58227785991625,1.25491991108173,20,nuclear receptor
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,101.646320350562,1.6001846353085012,26.15660702349629,1.41758140759789,21.1738733368031,101.058643704411,percent_activity,2,63.5216200104093,,1.47558954254655,1.47558954254655,1.16791946937272,20,nuclear receptor